vs
STANDARD BIOTOOLS INC.（LAB）与Perfect Moment Ltd.（PMNT）财务数据对比。点击上方公司名可切换其他公司
STANDARD BIOTOOLS INC.的季度营收约是Perfect Moment Ltd.的1.7倍（$19.6M vs $11.7M），Perfect Moment Ltd.净利率更高（0.8% vs -177.4%，领先178.2%），Perfect Moment Ltd.同比增速更快（0.8% vs -11.5%），Perfect Moment Ltd.自由现金流更多（$2.2M vs $-23.1M）
Standard BioTools（原Fluidigm公司）是一家美国生命科学工具企业，主营流式细胞术与组织成像分析用质谱流式系统，以及配套的检测试剂盒与试剂，同时供应自动化基因组分析仪器、各类微流控芯片（又称集成流体电路）及配套试剂耗材，全系列产品及应用场景均可提供定制检测方案与相关服务。
Perfect Moment Ltd是一家高端生活方式与户外服饰品牌，主打兼顾高性能与时尚设计的滑雪服、运动服饰及配套配件，面向高端户外与冬季运动消费群体，业务覆盖北美、欧洲、亚太等核心市场。
LAB vs PMNT — 直观对比
营收规模更大
LAB
是对方的1.7倍
$11.7M
营收增速更快
PMNT
高出12.2%
-11.5%
净利率更高
PMNT
高出178.2%
-177.4%
自由现金流更多
PMNT
多$25.3M
$-23.1M
损益表 — Q3 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $19.6M | $11.7M |
| 净利润 | $-34.7M | $93.0K |
| 毛利率 | 48.5% | 64.4% |
| 营业利润率 | -168.5% | 5.0% |
| 净利率 | -177.4% | 0.8% |
| 营收同比 | -11.5% | 0.8% |
| 净利润同比 | -28.8% | 103.7% |
| 每股收益（稀释后） | $-0.09 | $0.00 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LABPMNT
| Q4 25 | — | $11.7M | ||
| Q3 25 | $19.6M | $4.8M | ||
| Q2 25 | $21.8M | $1.5M | ||
| Q1 25 | $40.8M | $5.0M | ||
| Q4 24 | — | $11.7M | ||
| Q3 24 | $22.1M | $3.8M | ||
| Q2 24 | $22.5M | — | ||
| Q1 24 | $45.5M | — |
净利润LABPMNT
| Q4 25 | — | $93.0K | ||
| Q3 25 | $-34.7M | $-1.8M | ||
| Q2 25 | $-33.5M | $-3.8M | ||
| Q1 25 | $-26.0M | $-7.3M | ||
| Q4 24 | — | $-2.5M | ||
| Q3 24 | $-26.9M | $-2.7M | ||
| Q2 24 | $-45.7M | — | ||
| Q1 24 | $-32.2M | — |
毛利率LABPMNT
| Q4 25 | — | 64.4% | ||
| Q3 25 | 48.5% | 60.1% | ||
| Q2 25 | 48.8% | 60.4% | ||
| Q1 25 | 48.4% | 32.0% | ||
| Q4 24 | — | 54.8% | ||
| Q3 24 | 54.9% | 54.0% | ||
| Q2 24 | 46.1% | — | ||
| Q1 24 | 53.1% | — |
营业利润率LABPMNT
| Q4 25 | — | 5.0% | ||
| Q3 25 | -168.5% | -23.9% | ||
| Q2 25 | -118.1% | -207.5% | ||
| Q1 25 | -80.8% | -130.1% | ||
| Q4 24 | — | -11.1% | ||
| Q3 24 | -120.9% | -66.7% | ||
| Q2 24 | -134.5% | — | ||
| Q1 24 | -132.2% | — |
净利率LABPMNT
| Q4 25 | — | 0.8% | ||
| Q3 25 | -177.4% | -38.6% | ||
| Q2 25 | -153.7% | -259.4% | ||
| Q1 25 | -63.8% | -145.5% | ||
| Q4 24 | — | -21.3% | ||
| Q3 24 | -122.0% | -71.6% | ||
| Q2 24 | -203.3% | — | ||
| Q1 24 | -70.6% | — |
每股收益（稀释后）LABPMNT
| Q4 25 | — | $0.00 | ||
| Q3 25 | $-0.09 | $-0.06 | ||
| Q2 25 | $-0.09 | $-0.21 | ||
| Q1 25 | $-0.07 | $-0.45 | ||
| Q4 24 | — | $-0.15 | ||
| Q3 24 | $-0.07 | $-0.17 | ||
| Q2 24 | $-0.12 | — | ||
| Q1 24 | $-0.27 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $129.4M | $1.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $399.7M | $1.1M |
| 总资产 | $539.6M | $13.8M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资LABPMNT
| Q4 25 | — | $1.6M | ||
| Q3 25 | $129.4M | $393.0K | ||
| Q2 25 | $158.6M | $3.0M | ||
| Q1 25 | $150.9M | $6.2M | ||
| Q4 24 | — | $2.8M | ||
| Q3 24 | $210.6M | $725.0K | ||
| Q2 24 | $269.8M | — | ||
| Q1 24 | $287.1M | — |
总债务LABPMNT
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $1.9M | ||
| Q3 24 | $55.2M | $1.8M | ||
| Q2 24 | $55.1M | — | ||
| Q1 24 | $55.0M | — |
股东权益LABPMNT
| Q4 25 | — | $1.1M | ||
| Q3 25 | $399.7M | $981.0K | ||
| Q2 25 | $424.5M | $987.0K | ||
| Q1 25 | $454.6M | $1.9M | ||
| Q4 24 | — | $907.0K | ||
| Q3 24 | $489.3M | $2.7M | ||
| Q2 24 | $510.3M | — | ||
| Q1 24 | $577.3M | — |
总资产LABPMNT
| Q4 25 | — | $13.8M | ||
| Q3 25 | $539.6M | $15.0M | ||
| Q2 25 | $557.0M | $8.3M | ||
| Q1 25 | $579.6M | $13.3M | ||
| Q4 24 | — | $13.2M | ||
| Q3 24 | $681.5M | $13.3M | ||
| Q2 24 | $708.7M | — | ||
| Q1 24 | $777.7M | — |
负债/权益比LABPMNT
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 2.11× | ||
| Q3 24 | 0.11× | 0.67× | ||
| Q2 24 | 0.11× | — | ||
| Q1 24 | 0.10× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-22.2M | $2.3M |
| 自由现金流经营现金流 - 资本支出 | $-23.1M | $2.2M |
| 自由现金流率自由现金流/营收 | -118.1% | 19.1% |
| 资本支出强度资本支出/营收 | 4.5% | 0.3% |
| 现金转化率经营现金流/净利润 | — | 24.26× |
| 过去12个月自由现金流最近4个季度 | $-111.1M | — |
8季度趋势，按日历期对齐
经营现金流LABPMNT
| Q4 25 | — | $2.3M | ||
| Q3 25 | $-22.2M | $-7.2M | ||
| Q2 25 | $-20.7M | $-3.9M | ||
| Q1 25 | $-30.3M | $-1.1M | ||
| Q4 24 | — | $-1.0M | ||
| Q3 24 | $-27.9M | $-3.9M | ||
| Q2 24 | $-39.0M | — | ||
| Q1 24 | $-62.5M | — |
自由现金流LABPMNT
| Q4 25 | — | $2.2M | ||
| Q3 25 | $-23.1M | — | ||
| Q2 25 | $-22.6M | — | ||
| Q1 25 | $-35.3M | $-1.1M | ||
| Q4 24 | — | $-1.2M | ||
| Q3 24 | $-30.1M | $-3.9M | ||
| Q2 24 | $-41.0M | — | ||
| Q1 24 | $-63.3M | — |
自由现金流率LABPMNT
| Q4 25 | — | 19.1% | ||
| Q3 25 | -118.1% | — | ||
| Q2 25 | -103.6% | — | ||
| Q1 25 | -86.6% | -21.8% | ||
| Q4 24 | — | -10.6% | ||
| Q3 24 | -136.4% | -101.5% | ||
| Q2 24 | -182.2% | — | ||
| Q1 24 | -138.9% | — |
资本支出强度LABPMNT
| Q4 25 | — | 0.3% | ||
| Q3 25 | 4.5% | — | ||
| Q2 25 | 8.7% | — | ||
| Q1 25 | 12.4% | 0.3% | ||
| Q4 24 | — | 1.6% | ||
| Q3 24 | 10.2% | 1.0% | ||
| Q2 24 | 8.6% | — | ||
| Q1 24 | 1.7% | — |
现金转化率LABPMNT
| Q4 25 | — | 24.26× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LAB
| Consumables | $8.7M | 45% |
| Services And Other Revenue | $5.8M | 29% |
| Instruments | $5.1M | 26% |
PMNT
暂无分部数据
